专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO1993010140A1 OLIGONUCLEOTIDES HAVING MODIFIED ANIONIC MOIETIES 审中-公开
标题翻译：具有改性阴离子交换的寡核苷酸
公开(公告)号：WO1993010140A1
公开(公告)日：1993-05-27
申请号：PCT/US1992009809
申请日：1992-11-12
申请人： PHARMAGENICS, INC.
发明人： PHARMAGENICS, INC. , COOK, Alan, F.
IPC分类号： C07H21/04
CPC分类号： C07H21/00
摘要： An oligonucleotide wherein at least one nucleotide unit of the oligonucleotide includes a phosphonate moiety having structural formula (I), wherein X is: (R)n-COO , (R)n-SO3 , or (R)n-PO3 . R is a hydrocarbon, preferably an alkyl group, and most preferably a methyl group; n is 0 or 1. In a preferred embodiment, X is (CH2)n-COO . Such oligonucleotides have improved binding capabilities and increased resistance to nuclease activity, and may also be used as intermediates for the attachment of detectable markers.
摘要翻译：寡核苷酸，其中寡核苷酸的至少一个核苷酸单元包含具有结构式（I）的膦酸酯部分，其中X为：（R）n-COO - ，（R）n -SO 3 - 或（R）正PO3 <2->。 R是烃，优选烷基，最优选甲基; n是0或1.在优选的实施方案中，X是（CH 2）n -CO 2 - 。这样的寡核苷酸具有改善的结合能力和增加的对核酸酶活性的抗性，并且还可以用作连接可检测标记的中间体。

2. 发明专利

DE69216478D1 未知
公开(公告)号：DE69216478D1
公开(公告)日：1997-02-20
申请号：DE69216478
申请日：1992-06-10
申请人： UNIV JOHNS HOPKINS , PHARMAGENICS INC
发明人： VOGELSTEIN BERT , KINZLER KENNETH W , SHERMAN MICHAEL I
IPC分类号： A61B10/00 , C07K14/47 , C12N15/09 , C12P21/08 , C12Q1/02 , C12Q1/68 , G01N33/50 , G01N33/53 , G01N33/574 , G01N33/577 , G01N33/68 , A61K48/00 , C07H21/04 , C12Q1/70
摘要： Specific sequences in the human genome are the sites of strong binding of wild-type p53 protein, but not mutant forms of the protein. These sequences are used diagnostically to detect cells in which the These sequences are used diagnostically to detect cells in which the amount of wild-type p53 is diminished. The sequences can also be used to screen for agents which correct for loss of wild-type p53 to DNA in cancer cells.

3. 发明专利

AT147512T 未知
公开(公告)号：AT147512T
公开(公告)日：1997-01-15
申请号：AT92305333
申请日：1992-06-10
申请人： UNIV JOHNS HOPKINS , PHARMAGENICS INC
发明人： VOGELSTEIN BERT , KINZLER KENNETH W , SHERMAN MICHAEL I
IPC分类号： A61B10/00 , C07K14/47 , C12N15/09 , C12P21/08 , C12Q1/02 , C12Q1/68 , G01N33/50 , G01N33/53 , G01N33/574 , G01N33/577 , G01N33/68 , A61K48/00 , C07H21/04 , C12Q1/70
摘要： Specific sequences in the human genome are the sites of strong binding of wild-type p53 protein, but not mutant forms of the protein. These sequences are used diagnostically to detect cells in which the These sequences are used diagnostically to detect cells in which the amount of wild-type p53 is diminished. The sequences can also be used to screen for agents which correct for loss of wild-type p53 to DNA in cancer cells.

4. 发明专利

AU3144593A OLIGONUCLEOTIDES HAVING AMINOHYDROCARBON PHOSPHONATE MOIETIES 未知
公开(公告)号：AU3144593A
公开(公告)日：1993-06-28
申请号：AU3144593
申请日：1992-11-20
申请人： PHARMAGENICS, INC.
发明人： ALAN F COOK , REZA FATHI
IPC分类号： C07H21/02 , C07H21/00 , C07H21/04 , C12Q1/68

5. 发明专利

CA2070979C SEQUENCE SPECIFIC DNA BINDING BY P53 未知
公开(公告)号：CA2070979C
公开(公告)日：2006-01-03
申请号：CA2070979
申请日：1992-06-10
申请人： UNIV JOHNS HOPKINS , PHARMAGENICS INC
发明人： VOGELSTEIN BERT , KINZLER KENNETH W , SHERMAN MICHAEL I
IPC分类号： A61B10/00 , C12Q1/68 , A61K31/70 , A61K38/17 , A61K48/00 , C07H21/04 , C07K14/47 , C12N15/09 , C12P21/08 , C12Q1/02 , G01N33/50 , G01N33/53 , G01N33/574 , G01N33/577 , G01N33/68
摘要： Specific sequences in the human genome are the sites of strong binding of wild-type p53 protein, but not mutant forms of the protein. These sequences are used diagnostically to detect cells in which the amount of wild-type p53 is diminished. The sequences can also be used to screen for agents which correct for loss of wild-type p53 to DNA in cancer cells.

6. 发明专利

CA2244924A1 NON-NUCLEOTIDE PHOSPHOROUS ESTER OLIGOMERS 未知
公开(公告)号：CA2244924A1
公开(公告)日：1997-08-07
申请号：CA2244924
申请日：1997-01-22
申请人： PHARMAGENICS INC
发明人： FATHI REZA , RUDOLPH MORRIS J , GENTLES ROBERT G , COOK ALAN F
IPC分类号： C07F9/24 , C07F9/38 , C07F9/547 , C07F9/553 , C07F9/6509 , C07F9/6561 , C07H15/18
摘要： A phosphorus ester oligomer having structure (I) wherein A can be the same or different in each monomeric unit and each is independently selected from the group consisting of oxygen, sulfur, lower alkyl, substituted or unsubstituted alkylamino, substituted or unsubstituted arylamino and aminoalkyl; B1 and B2 can be the same or different and each is independently selected from hydrogen, lower alkyl, a labelling group, a protecting group, a phosphoramidate or a phosphomonoester; R1 can be the same or different in each monomeric unit, and in at least one of the non-nucleotide monomeric units, R1 is independently selected from the group consisting of a condensation product of (i) a nonvicinal diol attached to a hydrogen bond donor functionality; (ii) a hydrogen bond acceptor selected from an ether, a purine or pyrimidine substituted 1,2diol or a disubstituted heterocycle; (iii) a non-vicinal diol attached to a hydrophobic functionality or a vicinal diol attached to an aliphatic or alicyclic hydrophobic functionality; (iv) a diol attached to a ring substituted anionic functionality and (v) a cationic moiety attached to a nonvicinal or alicyclic diol, any of which can further include a detectable label, and n is at least one. Preferred R1 moieties include condensation products of heterocyclic diols, alicyclic diols, and polycyclic diols. Also the non-nucleotide monomers thereof, combinatorial library mixtures of the oligomers and the use of the oligomers as selective target-binding compounds.

7. 发明专利

DK0518650T3 未知
公开(公告)号：DK0518650T3
公开(公告)日：1997-01-27
申请号：DK92305333
申请日：1992-06-10
申请人： UNIV JOHNS HOPKINS , PHARMAGENICS INC
发明人： VOGELSTEIN BERT , KINZLER KENNETH W , SHERMAN MICHAEL I
IPC分类号： A61B10/00 , C07K14/47 , C12N15/09 , C12P21/08 , C12Q1/02 , C12Q1/68 , G01N33/50 , G01N33/53 , G01N33/574 , G01N33/577 , G01N33/68 , C07H21/04 , A61K48/00 , G01N33/569
摘要： Specific sequences in the human genome are the sites of strong binding of wild-type p53 protein, but not mutant forms of the protein. These sequences are used diagnostically to detect cells in which the These sequences are used diagnostically to detect cells in which the amount of wild-type p53 is diminished. The sequences can also be used to screen for agents which correct for loss of wild-type p53 to DNA in cancer cells.

8. 发明专利

AU7112594A Method for selection of targets and nucleic acids which modulate target activity 未知
公开(公告)号：AU7112594A
公开(公告)日：1995-01-17
申请号：AU7112594
申请日：1994-06-17
申请人： PHARMAGENICS INC
发明人： BEUTEL BRUCE A , STOLLER TIMOTHY J , COPPOLA GEORGE R , SCHURDAK MARK E , BEAUDRY GARY A , BERTELSEN ARTHUR H
IPC分类号： C12N15/113 , C12Q1/68 , C07H21/02 , C07H21/04 , G01N33/50

9. 发明专利

ES2097878T3 未知
公开(公告)号：ES2097878T3
公开(公告)日：1997-04-16
申请号：ES92305333
申请日：1992-06-10
申请人： UNIV JOHNS HOPKINS , PHARMAGENICS INC
发明人： VOGELSTEIN BERT , KINZLER KENNETH W , SHERMAN MICHAEL I
IPC分类号： A61B10/00 , C07K14/47 , C12N15/09 , C12P21/08 , C12Q1/02 , C12Q1/68 , G01N33/50 , G01N33/53 , G01N33/574 , G01N33/577 , G01N33/68 , A61K48/00 , C07H21/04 , C12Q1/70
摘要： Specific sequences in the human genome are the sites of strong binding of wild-type p53 protein, but not mutant forms of the protein. These sequences are used diagnostically to detect cells in which the These sequences are used diagnostically to detect cells in which the amount of wild-type p53 is diminished. The sequences can also be used to screen for agents which correct for loss of wild-type p53 to DNA in cancer cells.

10. 发明专利

AU3636995A Bridged and unbridged quadruplex/duplex oligonucleotides 未知
公开(公告)号：AU3636995A
公开(公告)日：1996-05-02
申请号：AU3636995
申请日：1995-09-20
申请人： PHARMAGENICS INC
发明人： MACAYA ROMAN F , GAO HETIAN , JOESTEN MICHAEL E , BEUTEL BRUCE A , BERTELSEN ARTHUR H , COOK ALAN F
IPC分类号： A61K38/00 , C07H21/00 , C12N15/113 , C12Q1/68 , G01N33/80 , A61K31/70 , C07H21/04 , C12Q1/56 , G01N33/53 , G01N33/86

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式